MIL62
MIL62 is a glycoengineered type II anti-CD20 monoclonal antibody with a nearly completely afucosylated N-glycans in Fc region. MIL62 shows enhanced affinity for the FcγRIIIa receptors and direct B-cell killing effects. MIL62 has antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MIL62 can be used for the study of non-Hodgkin lymphoma (NHL) [1].
Product Specifications
UNSPSC
12352203
Target
CD20
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
References & Citations
[1]Shi Y, et al. Efficacy and safety of MIL62, a novel glycoengineered type II anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b/2 trial. EClinicalMedicine. 2024 Jun 20;73:102702.
Shipping Conditions
Room temperature
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P991514/
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
31515141 1x10<sup>6</sup> cells/1.0ml
NBPF18P CRISPR Knock Out 293T Cell Line (Human)
Ask
View Details